1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Revisions of Precautions Required for 26 Ingredients
January 28, 2002
- JFMDA Prepares Guide on Handling of Used Medical Devices
January 28, 2002
- REGULATORY NEWS IN BRIEF
January 28, 2002
- RIKEN Invites Companies to Collaborate in Gene Polymorphism Analysis
January 28, 2002
- Kitasato Univ. Hospital Upgrades Immediate PMS System
January 28, 2002
- NanoCarrier Contracts with GSK for DDS
January 28, 2002
- Tsuruha: Sales Up 19.8%, Profits Up 27% in Semi-annual Results
January 28, 2002
- Theme for 2002 Baelz Prize Decided
January 28, 2002
- Kokuho Chuokai Welcomes On-line Applications for Reimbursement
January 28, 2002
- Switch to Marketing Approval to Increase Efficiency: FPMAJ President
January 28, 2002
- Link Staff Sets Up New Firm to Support Hospitals M&As
January 28, 2002
- Over 90% of JPMA Members to Prepare Compliance Programs: Survey
January 28, 2002
- Importance of Hospital Cost Management Stressed: Seminar
January 28, 2002
- Good Initial Market Reactions Reported for Eli Lilly's Humalog
January 28, 2002
- Sato Pharm to Accelerate Development of Switch OTC Drugs
January 28, 2002
- WEBSITE NEWS
January 28, 2002
- OTC NEWS IN BRIEF
January 28, 2002
- BUSINESS NEWS IN BRIEF
January 28, 2002
- Takara Obtains Rights for Cycling Probe Technique from IDB of Canada
January 28, 2002
- Meiji Seika to Concentrate on Infectious Diseases
January 21, 2002
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…